December 2008

► NEW DRUGS	Standard Plan	Select Plan	Closed Plan
Alvesco (ciclesonide)
An inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. Alvesco is not indicated for the relief of acute bronchospasm. In a limited category (Asthma/COPD)	Brand copay.	Third tier, non-preferred brand copay.	Not covered.

► LINE EXTENSIONS	Standard Plan	Select Plan	Closed Plan
PrandiMet
A combination of repaglinide and metformin which is indicated as an adjunct to diet and exercise to improve control of blood sugar in adults with Type 2 diabetes mellitus who are already being treated with the same agents alone or in combination. Prior therapy review applies as an electronic step edit. The electronic edit reviews claim history for prior use of two of the following agents: metformin, a sulfonylurea, a TZD.. PranidiMet has not yet been released into the market but will be a non-preferred agent with the prior review edit in place when available. In a limited category (Anti-Diabetic)	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.

► DRUG CLASS REVIEW Intranasal Antihistamines	Standard Plan	Select Plan	Closed Plan
Astelin (azelatine HCL nasal spray)
An antihistamine indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and children 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and children 12 years and older. In a limited category (allergy-intranasal) Quantity limits apply Quantity limits effective February 1, 2009.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Patanase (olopatadine nasal solution)
An antihistamine indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older. In a limited category (allergy-intranasal) Quantity limits apply Added to preferred status, effective January 1, 2009.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.

► DRUG CLASS REVIEW Growth Hormones	Standard Plan	Select Plan	Closed Plan
Nutropin, Nutropin AQ, Saizen
Full Class review of Growth Hormones used in the treatment of growth hormone deficiency. Nutropin and Nutropin AQ remain preferred agents. Saizen is added to Preferred Product List, effective February 1, 2009. Coverage determined by the benefit design chosen by the plan sponsor. In a limited category (growth hormones) Nonstandard category Prior authorization applies Specialty Pharmacy Program	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the preferred brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the preferred brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.
Genotropin, Humatrope, Norditropin, Omnitrope, Serostim, Tev-Tropin, Zorbtive
Full Class review of Growth Hormones used in the treatment of growth hormone deficiency. Humatrope and Norditropin are removed from preferred status, effective February 1, 2009. All other listed products remain non-preferred. Coverage determined by the benefit design chosen by the plan sponsor. In a limited category (growth hormones) Nonstandard category Prior authorization applies Specialty Pharmacy Program	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	If the customer has the Specialty Pharmacy Program (SPP), this product may be obtained through the specialty pharmacy network at the third tier, non-preferred brand copay. If the customer does not have the SPP it may be considered under the pharmacy benefit. Coverage and pharmacy provider(s) determined by the benefit design selected by the plan sponsor.	Not covered.

► PPL UPDATES	Standard Plan	Select Plan	Closed Plan
Sular 8.5 mg, 17 mg, 25.5 mg, and 34 mg tablets (nisoldipine SR tablets)
Indicated for the treatment of hypertension either alone, or in combination with other antihypertensive agents. Sular is being moved to third tier nonpreferred status. In a limited category (blood pressure - calcium channel blockers)	Brand copay.	Third tier, non-preferred brand copay.	Not covered.

► BRANDS WITH GENERICS AVAILABLE	Standard Plan	Select Plan	Closed Plan
No products with new generics reviewed at November meeting

► Clinical Programs: DACON	Standard Plan	Select Plan	Closed Plan
Avapro, Avalide, Benicar, Benicar-HCT, Diovan, Diovan-HCT, Aggrenox, Ambien CR
Listed items will be added to the DACON program, effective February 1, 2009	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Allegra, Allegra D, Clarinex (all dose forms), Atacand, Atacand-HCT, Cozaar, Hyzaar, Micardis, Micardis-HCT, Teveten, Teveten-HCT
Listed items will be added to the DACON program, effective February 1, 2009	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.

► Clinical Programs: Quantity Limits	Standard Plan	Select Plan	Closed Plan
Nasonex, Veramyst
Listed items will be added to the Quantity Limit program, effective February 1, 2009	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Beconase AQ, Nasacort AQ, Rhinocort AQ
Listed items will be added to the Quantity Limit program, effective February 1, 2009	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third tier, non-preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.
Lidoderm (lidocaine topical patch)
Limit will change from a quantity of one box per copay to three boxes (90 patches) per month (3 patches daily)	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.

	December 2008



Innoviant's Business Committee meets monthly to evaluate product status (tier placements) and new prescription products approved by the Food and Drug Administration (FDA). Decisions made by the Innoviant Business Committee are based on information and recommendations provided by Prescription Solutions' National Pharmacy & Therapeutics Committee (NPTC). The P&T is comprised of independent physician providers, affiliated plan physicians and pharmacists. The following table summarizes the decisions made at the November committee meetings. All changes are effective February 1, 2009 unless otherwise noted. Current information related to Innoviant and its offerings is available at www.innoviant.com. A copy of this newsletter can also be found on the website (http://www.innoviant.com/customers/publications/default.asp).